The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
One-Year Results with Extended-Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients
Open accessAbstract
Once-daily tacrolimus extended-release formulation (Prograf XL, formerly referred to as MR or MR4) was compared with the twice-a-day tacrolimus formulation (TAC) and cyclosporine microemulsion (CsA), all administered in combination with mycophenolate mofetil (MMF), corticosteroids and basiliximab induction, in a phase 3, randomized (1:1:1), open-label trial in 638 de novo kidney transplant recipients. In combination with MMF and corticosteroids, XL had an efficacy profile comparable to TAC and CsA. XL/MMF and TAC/MMF were statistically noninferior at 1-year posttransplantation to CsA/MMF for the primary efficacy endpoint, efficacy failure (death, graft loss, biopsy-confirmed acute rejection (BCAR) or lost to follow-up). One-year patient and graft survival were 98.6% and 96.7% in the XL/MMF group, 95.7% and 92.9% in TAC/MMF group and 97.6% and 95.7% in CsA/MMF group. The safety profile of XL in comparison with CsA was similar to that observed with TAC in this study and consistent with previously published reports of TAC in comparison with CsA. The results support the safety and efficacy of tacrolimus in combination with MMF, corticosteroids and basiliximab induction, as well as XL as a safe and effective once-daily dosing alternative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Heisel, O., Heisel, R., Balshaw, R., & Keown, P. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00372.x · Cited by 506
Cited by
Vincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957
Budde, K., Becker, T., Arns, W., Sommerer, C., Reinke, P., Eisenberger, U., Kramer, S., Fischer, W., Gschaidmeier, H., & Pietruck, F. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62318-5 · Cited by 359
Vanrenterghem, Y., Bresnahan, B., Campistol, J., Durrbach, A., Grinyó, J., Neumayer, H.-H., Lang, P., Larsen, C. P., Mancilla-Urrea, E., Pestana, J. M., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e31820c10eb · Cited by 183
Tremblay, S., Nigro, V., Weinberg, J., Woodle, E. S., & Alloway, R. R. (2017) · American Journal of Transplantation · doi:10.1111/ajt.13935 · Cited by 171
Andrews, L. M., Li, Y., De Winter, B. C. M., Shi, Y.-Y., Baan, C. C., Van Gelder, T., & Hesselink, D. A. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1395413 · Cited by 142
Metadata
- Authors
- Silva, H., Yang, H., Abouljoud, M., Kuo, P., Wisemandle, K., Bhattacharya, P., Dhadda, S., Holman, J., Fitzsimmons, W., & Roy First, M.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 7
- Issue
- 3
- Pages
- 595-608
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W2078939327
- Cited by
- 177
- References
- 2
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: One-Year Results with Extended-Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients. https://app.cochat.ai/papers/10.1111/j.1600-6143.2007.01661.x
- The paper
- Silva, H., Yang, H., Abouljoud, M., Kuo, P., Wisemandle, K., Bhattacharya, P., Dhadda, S., Holman, J., Fitzsimmons, W., & Roy First, M. (2007). One-Year Results with Extended-Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2007.01661.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.